10-Q: America Great Health Reports Increased Sales but Continues to Face Going Concern Challenges in Q2 2025

America Great Health's Q2 2025 report shows increased sales due to new product launches, but the company still faces net losses and substantial doubt about its ability to continue as a going concern.

Summary

• America Great Health's Q2 2025 report reveals increased sales, primarily driven by the introduction of new products.
• Sales for the six months ended December 31, 2024, reached $231,065, compared to $104,987 for the same period in 2023.
• The cost of goods sold also increased to $19,177 from $8,702 year-over-year, correlating with the new product launches.
• Despite the sales increase, the company reported a net loss of $340,670 for the six months ended December 31, 2024, an improvement from the $406,325 loss in the prior year.
• Operating expenses rose to $403,261 from $325,090, attributed to increased advertising and payroll expenses.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern, given recurring net losses and a shareholders' deficit of $5,576,377 as of December 31, 2024.
• The company's ability to continue as a going concern is dependent on securing additional sources of capital and the success of the company's plan.
• As of December 31, 2024, the company had a cash balance of $36,040.
• The company intends to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.
• The company is raising the additional capital to achieve profitable operations.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While sales increased, the company continues to face significant financial challenges, including net losses, a substantial shareholders' deficit, and doubts about its ability to continue as a going concern. The reliance on related-party loans also raises concerns.

Positives

• Sales increased significantly due to the launch of new products.
• The net loss decreased compared to the same period in the previous year.
• Gross profit increased to $211,888 from $96,285 for the six months ended December 31, 2024 and 2023, respectively.

Negatives

• The company continues to experience net losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a significant shareholders' deficit of $5,576,377.
• The company is heavily reliant on loans and advances from its majority shareholder.
• The company has negative working capital of $3,496,425.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company is dependent on securing additional capital and achieving profitable operations.
• The company faces challenges in managing liquidity and maintaining sufficient cash flow.
• The company's internal controls over financial reporting are not effective.
• The company lacks a functioning audit committee and independent directors.

Future Outlook

The company's future performance depends on securing additional capital and achieving profitable operations. The company intends to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

Management Comments

• Our mission is to invest in innovative technologies integrated with business development in the healthcare ecosystem.
• We are focused on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing, cell therapy and regenerational medicine and supplements manufacturing and sales.

Industry Context

The company operates in the healthcare ecosystem, focusing on innovative technologies and business development. The report highlights the company's focus on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing, cell therapy and regenerational medicine and supplements manufacturing and sales.

Comparison to Industry Standards

• It is difficult to compare America Great Health's results to industry standards due to its unique business model and focus on emerging healthcare technologies.
• The company's reliance on related-party loans and its negative working capital position are concerning compared to industry peers with more stable financial structures.
• The company's focus on R&D in areas like anti-cancer peptides and stem cell technology could provide a competitive advantage if successful, but these ventures are inherently risky and capital-intensive.

Legal Proceedings

• The company is not a party to or otherwise involved in any legal proceedings.

Related Party Transactions

• During the six months ended December 31, 2024, the Companys current majority shareholder advanced $76,537 to the Company as working capital and the Company repaid $116,665 to the shareholder.
• As of December 31, 2024 and June 30, 2024, the Company owed its current majority shareholder $1,070,068 and $1,110,196, respectively.
• The advances are non-interest bearing and are due on demand.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees' job security is uncertain due to the company's financial challenges.
• Customers may be affected if the company is unable to continue operations.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company needs to secure additional capital to address its financial challenges.
• The company needs to achieve profitable operations to ensure its long-term viability.
• The company needs to improve its internal controls over financial reporting.

Key Dates

Keywords

going concern, net loss, sales increase, financial performance, America Great Health, Q2 2025, 10-Q, financial statements